This multicenter clinical trial evaluated the clinical efficacy of sequential treatments in patients with metastatic colorectal cancer with G12C mutation of the KRAS gene who received intensive first-line double or triple first-line chemotherapy (including irinotecan- or oxaliplatin-based chemotherapy).
In the development of the trial, only moderate overall response rates were observed with first-line double or triple chemotherapy. In addition, only 62% and 36% of patients were eligible for second and third lines of treatment, respectively, after progression on first-line therapy.
The conclusions drawn from the trial highlight that the KRASG12C mutation is rare but correlates with aggressive disease and lower response to chemotherapy in patients with metastatic colorectal cancer. Furthermore, they suggest that treatment with first-line FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) may be a valid option for eligible patients.
